company background image
1752 logo

Nang Kuang Pharmaceutical TWSE:1752 Stock Report

Last Price

NT$53.10

Market Cap

NT$5.4b

7D

-1.3%

1Y

-16.1%

Updated

14 Jun, 2024

Data

Company Financials

Nang Kuang Pharmaceutical Co., Ltd.

TWSE:1752 Stock Report

Market Cap: NT$5.4b

1752 Stock Overview

Engages in the manufacturing, processing, trading, import, and export of pharmaceuticals and medical devices in Taiwan and internationally.

1752 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance1/6
Financial Health6/6
Dividends2/6

Nang Kuang Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nang Kuang Pharmaceutical
Historical stock prices
Current Share PriceNT$53.10
52 Week HighNT$64.90
52 Week LowNT$43.85
Beta0.26
1 Month Change15.06%
3 Month Change14.69%
1 Year Change-16.11%
3 Year Change36.86%
5 Year Change76.41%
Change since IPO213.37%

Recent News & Updates

Nang Kuang Pharmaceutical Co., Ltd.'s (TWSE:1752) 28% Price Boost Is Out Of Tune With Earnings

May 22
Nang Kuang Pharmaceutical Co., Ltd.'s (TWSE:1752) 28% Price Boost Is Out Of Tune With Earnings

Recent updates

Nang Kuang Pharmaceutical Co., Ltd.'s (TWSE:1752) 28% Price Boost Is Out Of Tune With Earnings

May 22
Nang Kuang Pharmaceutical Co., Ltd.'s (TWSE:1752) 28% Price Boost Is Out Of Tune With Earnings

Some Investors May Be Willing To Look Past Nang Kuang Pharmaceutical's (TWSE:1752) Soft Earnings

Apr 02
Some Investors May Be Willing To Look Past Nang Kuang Pharmaceutical's (TWSE:1752) Soft Earnings

Nang Kuang Pharmaceutical (GTSM:1752) Has A Pretty Healthy Balance Sheet

Mar 20
Nang Kuang Pharmaceutical (GTSM:1752) Has A Pretty Healthy Balance Sheet

Should You Or Shouldn't You: A Dividend Analysis on Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

Mar 03
Should You Or Shouldn't You: A Dividend Analysis on Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

Declining Stock and Decent Financials: Is The Market Wrong About Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)?

Feb 13
Declining Stock and Decent Financials: Is The Market Wrong About Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)?

Nang Kuang Pharmaceutical's (GTSM:1752) Stock Price Has Reduced 17% In The Past Five Years

Jan 26
Nang Kuang Pharmaceutical's (GTSM:1752) Stock Price Has Reduced 17% In The Past Five Years

Estimating The Fair Value Of Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

Jan 08
Estimating The Fair Value Of Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

Here's How We Evaluate Nang Kuang Pharmaceutical Co., Ltd.'s (GTSM:1752) Dividend

Nov 29
Here's How We Evaluate Nang Kuang Pharmaceutical Co., Ltd.'s (GTSM:1752) Dividend

Shareholder Returns

1752TW PharmaceuticalsTW Market
7D-1.3%0.5%1.9%
1Y-16.1%5.9%27.4%

Return vs Industry: 1752 underperformed the TW Pharmaceuticals industry which returned 5.9% over the past year.

Return vs Market: 1752 underperformed the TW Market which returned 27.4% over the past year.

Price Volatility

Is 1752's price volatile compared to industry and market?
1752 volatility
1752 Average Weekly Movement5.0%
Pharmaceuticals Industry Average Movement4.2%
Market Average Movement4.7%
10% most volatile stocks in TW Market8.4%
10% least volatile stocks in TW Market2.2%

Stable Share Price: 1752 has not had significant price volatility in the past 3 months.

Volatility Over Time: 1752's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1963n/aYu-Bei Wangwww.nangkuang.com.tw

Nang Kuang Pharmaceutical Co., Ltd. engages in the manufacturing, processing, trading, import, and export of pharmaceuticals and medical devices in Taiwan and internationally. The company provides parenterals, aseptic parenterals, lyophilized injections, pre-filled syringes, and pre-mixed IV infusion bags, as well as tablets, capsules, topical products, and oral suspensions. It also offers various products in the areas of cardiovascular system, gastrointestinal system, nervous system, alimentary and metabolism, blood, antineoplastic and immunomodulatory, musculo-skeletal system, respiratory system, dermatological, genito-urinary and sex hormone, systemic hormone, systemic antibacterial, and cosmetics, as well as hospital solutions.

Nang Kuang Pharmaceutical Co., Ltd. Fundamentals Summary

How do Nang Kuang Pharmaceutical's earnings and revenue compare to its market cap?
1752 fundamental statistics
Market capNT$5.36b
Earnings (TTM)NT$159.13m
Revenue (TTM)NT$2.11b

33.7x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1752 income statement (TTM)
RevenueNT$2.11b
Cost of RevenueNT$1.38b
Gross ProfitNT$723.51m
Other ExpensesNT$564.38m
EarningsNT$159.13m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.58
Gross Margin34.36%
Net Profit Margin7.56%
Debt/Equity Ratio17.7%

How did 1752 perform over the long term?

See historical performance and comparison

Dividends

3.8%

Current Dividend Yield

127%

Payout Ratio

Does 1752 pay a reliable dividends?

See 1752 dividend history and benchmarks
When do you need to buy 1752 by to receive an upcoming dividend?
Nang Kuang Pharmaceutical dividend dates
Ex Dividend DateJul 04 2024
Dividend Pay DateJul 31 2024
Days until Ex dividend19 days
Days until Dividend pay date46 days

Does 1752 pay a reliable dividends?

See 1752 dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.